Science-based guidance for their bodies
The female reproductive system is an intricate network designed for ovulation, fertilization, and pregnancy support. Understanding each component helps optimize your chances of conception and healthy pregnancy outcomes. Recent advances in reproductive imaging and genomics have dramatically deepened our understanding of how each structure communicates at a cellular level.
The ovaries serve dual functions: producing mature eggs for fertilization and secreting essential reproductive hormones including estrogen, progesterone, and small amounts of testosterone. Each month during your fertile years, typically 1,000 eggs begin the maturation process, but usually only one becomes the dominant follicle ready for ovulation. The process of follicle selection is governed by a delicate interplay of follicle-stimulating hormone (FSH), luteinizing hormone (LH), and local intra-ovarian growth factors.
Emerging research into ovarian aging has revealed that mitochondrial dysfunction in oocytes is a primary driver of age-related fertility decline. A 2021 study in Nature Aging demonstrated that mitochondrial biogenesis supplements, including CoQ10, may slow this process, offering potential interventions for women trying to conceive in their late 30s.
The average menstrual cycle lasts 28 days, though healthy cycles range from 21 to 35 days. It is divided into the follicular phase (days 1–14) and the luteal phase (days 15–28). During the follicular phase, rising FSH recruits a cohort of follicles while estrogen thickens the endometrium. The LH surge, typically occurring 36 hours before ovulation, triggers the final maturation and release of the egg.
During the luteal phase, the ruptured follicle transforms into the corpus luteum, producing progesterone to stabilize the endometrium for potential implantation. If fertilization does not occur, the corpus luteum degenerates, progesterone falls, and menstruation begins. A 2019 study in JCEM found that luteal phase defects — characterized by inadequate progesterone — may account for up to 10% of unexplained infertility cases.
These delicate, finger-like structures capture released eggs during ovulation and provide the optimal environment for fertilization. The fallopian tubes are lined with tiny hairs called cilia that help transport the egg toward the uterus. Each tube is divided into four anatomical segments: the fimbriae (the finger-like capturing end), the infundibulum, the ampulla (the widest section where fertilization occurs), and the isthmus (the narrow segment connecting to the uterus).
Tubal health is critical for conception success. Studies show that even minor tubal damage can reduce fertility by up to 50%, making conditions like pelvic inflammatory disease or endometriosis significant concerns for women trying to conceive. The cilia lining the tubal epithelium beat approximately 10 times per second to propel the egg; dysfunction of these cilia, sometimes caused by chlamydia infection, is a leading cause of ectopic pregnancy.
The uterus consists of three layers: the outer perimetrium, the muscular myometrium, and the inner endometrium. The endometrium undergoes monthly changes in preparation for potential pregnancy, thickening under estrogen influence and becoming receptive to implantation under progesterone's effect. The non-pregnant uterus weighs approximately 60–80g and measures 7–8 cm in length; by term, it weighs over 1 kg and can hold a volume of 4–5 liters.
Uterine fibroids (leiomyomas) affect up to 70% of women by age 50 and are particularly prevalent in women of African descent. A 2021 NIH-funded cohort study found that submucosal fibroids (those impinging on the uterine cavity) reduce natural conception rates by up to 70% and IVF success rates by 40%, underscoring the importance of early detection.
Once thought to be sterile, the uterine cavity has been found to harbor a distinct microbial community. Research published in American Journal of Reproductive Immunology in 2022 showed that a non-Lactobacillus-dominant endometrial microbiome is associated with significantly lower implantation and pregnancy rates in IVF patients. Disruption by pathogens such as Gardnerella or Streptococcus may impair the uNK cell environment critical for implantation.
The cervix produces different types of mucus throughout your menstrual cycle, serving as both a barrier and facilitator for sperm. During your fertile window, cervical mucus becomes thin, stretchy, and alkaline — creating optimal conditions for sperm survival and transport. Cervical mucus at mid-cycle forms microscopic channels called "crypts" that can store viable sperm for up to 5 days, creating a biological reservoir that extends the fertilization window.
The cervix also serves as an immune sentinel: cervical mucus contains immunoglobulin A (IgA) antibodies and antimicrobial peptides that neutralize pathogens while permitting sperm passage during the fertile window — a remarkable example of selective biological permeability.
Male fertility depends on continuous sperm production, proper hormone balance, and effective sperm delivery. Unlike women's monthly cycles, men produce sperm continuously from puberty throughout life, generating approximately 1,500 sperm per heartbeat. However, male fertility is not static — emerging evidence shows significant age-related decline and pronounced environmental sensitivity.
The testes contain seminiferous tubules where spermatogenesis occurs, along with Leydig cells that produce testosterone. Temperature regulation is crucial — the testes hang outside the body to maintain a temperature 2–3°C below core body temperature for optimal sperm production. Sertoli cells within the tubules act as "nurse cells," providing structural and nutritional support to developing sperm and forming the blood-testis barrier that protects maturing cells from immune attack.
Beyond conventional semen analysis, sperm DNA fragmentation (SDF) has emerged as a critical fertility biomarker. High SDF — defined as fragmentation index above 25% by the SCSA test — is associated with reduced natural conception, higher miscarriage rates, and poorer IVF/ICSI outcomes even when basic semen parameters appear normal.
Newly formed sperm spend 2–3 weeks in the epididymis, gaining motility and the ability to fertilize eggs. During this transit, sperm undergo a series of protein modifications to their plasma membrane, acquire forward progressive motility, and develop zona-binding capacity. The vas deferens then transport mature sperm during ejaculation, mixing with seminal fluid from the prostate and seminal vesicles. Seminal plasma contains fructose (primary sperm energy source), zinc, citric acid, prostaglandins, and proteolytic enzymes that liquefy semen after ejaculation.
Sperm production is regulated by the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus releases GnRH in pulses, stimulating the pituitary to release FSH (which drives spermatogenesis via Sertoli cells) and LH (which stimulates Leydig cell testosterone production). Testosterone feeds back to suppress GnRH and LH, forming a self-regulating loop. Exogenous testosterone supplementation — including anabolic steroids — suppresses this axis and causes testicular atrophy and azoospermia, a fact poorly understood by many men using testosterone for non-medical purposes.
During preconception, focus on optimizing ovarian function through proper nutrition, maintaining healthy body weight, and ensuring adequate folate levels. Research shows that women who take folic acid supplements for at least one month before conception reduce neural tube defect risk by up to 70%.
Body weight has a significant bidirectional effect on fertility. Both underweight (BMI below 18.5) and overweight (BMI above 25) are associated with ovulatory dysfunction. A 2020 ACOG committee opinion noted that even modest weight loss of 5–10% in overweight women can restore ovulation in 55–100% of cases.
Among the dietary patterns studied in reproductive medicine, a Mediterranean-style diet has shown some of the most consistent associations with favourable fertility outcomes. However, most of this evidence is observational, and it does not establish that following a Mediterranean diet directly increases a person's chance of pregnancy or live birth.
This combination produces a diet relatively rich in fibre, monounsaturated and polyunsaturated fats, omega-3 fatty acids, folate, polyphenols and other antioxidant compounds. These nutrients may influence several biological pathways relevant to reproduction, including glucose and insulin regulation, oxidative stress, vascular function and inflammatory signalling.
One proposed explanation for the association between Mediterranean-style eating and reproductive health is its effect on chronic inflammation. Mediterranean dietary interventions have been shown in broader populations to reduce some inflammatory biomarkers, including C-reactive protein (CRP), although the magnitude and consistency of these effects vary between studies.
Inflammatory and oxidative pathways are also involved in normal reproductive physiology. Controlled inflammatory signalling participates in ovulation, endometrial remodelling, implantation and placental development. Problems may arise when these processes become dysregulated rather than simply because "inflammation is bad."
Oxidative stress is another biologically plausible connection.
Mediterranean-style diets provide antioxidant compounds from vegetables, fruits, olive oil, legumes and nuts, as well as unsaturated fatty acids that may support a healthier metabolic environment. Whether these effects directly improve human egg quality, implantation or live-birth rates remains uncertain.
Metabolic health provides another potential link between diet and fertility. Insulin resistance and hyperinsulinaemia can influence ovarian steroid production and sex hormone-binding globulin (SHBG), and are particularly relevant in many people with polycystic ovary syndrome (PCOS).
Mediterranean-style dietary patterns can improve several cardiometabolic measures, including glycaemic control and insulin sensitivity. These effects make the diet a reasonable component of overall lifestyle management for people with metabolic dysfunction or PCOS. However, improvement in insulin sensitivity should not automatically be interpreted as proof of increased pregnancy or live-birth rates.
The strongest evidence currently comes from observational studies of women attempting conception or undergoing assisted reproductive technology (ART). Several studies have found that women reporting greater adherence to Mediterranean-style dietary patterns have higher rates of clinical pregnancy or live birth. Other studies, however, have found little or no association.
The apparently large effect size from this analysis therefore needs considerable caution. It was not evidence that a Mediterranean diet "doubles the chance of having a baby." The pooled live-birth result came from only two observational studies, involved a relatively small number of women, and could have been influenced by differences between women who ate Mediterranean-style diets and those who did not.
These differences are difficult to completely remove statistically. People who closely follow Mediterranean-style diets may also differ in physical activity, smoking, alcohol intake, body composition, socioeconomic circumstances, supplement use, sleep, healthcare access and other behaviours that independently influence reproductive outcomes. This is known as residual confounding and is one of the major limitations of observational nutrition research.
A major 2023 systematic scoping review published in Human Reproduction Update examined 36 studies of female preconception nutrition, including 31 prospective studies. Of all the dietary patterns examined, greater adherence to a Mediterranean diet showed the strongest and most consistent association with clinical pregnancy.
More recent evidence continues to support this cautious interpretation. A 2025 systematic review examining Mediterranean-diet adherence and assisted reproduction identified eight relevant studies. Four reported significant favourable associations with outcomes such as embryo development, pregnancy or live birth, while four found no significant association. The authors concluded that a potential relationship exists, but that the evidence remains limited and additional high-quality research is required.
Clinical pregnancy occurred in 50.0% of women in the highest-adherence group compared with 29.1% in the lowest-adherence group, while live birth occurred in 48.8% compared with 26.6%. However, this association was not detected in women aged 35 years or older.
These results attracted considerable attention, but the study was observational. Women were not randomly assigned to Mediterranean and non-Mediterranean diets, so it cannot demonstrate that the diet itself caused the difference in IVF outcomes. Later studies have also failed to consistently reproduce such large effects.
It is also misleading to say that Mediterranean eating improves fertility simply because it "reduces inflammation in PCOS and endometriosis." Both conditions are biologically complex.
PCOS is associated with varying degrees of insulin resistance, hyperandrogenism, metabolic dysfunction and low-grade inflammation. Improving overall diet quality may improve metabolic health and can form part of PCOS management, particularly when insulin resistance is present. However, there is not yet strong evidence that Mediterranean-diet adherence itself reliably restores ovulation or increases live-birth rates.
Endometriosis involves chronic inflammatory and immune signalling within and around ectopic endometrial-like tissue. Diet has therefore become an important area of research, and Mediterranean-style eating has been investigated for possible effects on inflammation, oxidative stress and endometriosis-associated symptoms. Evidence that it improves fertility or reverses endometriosis-associated infertility, however, is currently insufficient.
The Mediterranean diet is also unlikely to work through one "fertility food." Extra-virgin olive oil provides monounsaturated fats and polyphenols; fish provides long-chain omega-3 fatty acids; legumes and whole grains provide fibre and slower-digesting carbohydrates; and vegetables, fruits, nuts and seeds provide numerous micronutrients and phytochemicals.
Researchers increasingly study the entire dietary pattern because foods and nutrients interact. A person's overall dietary pattern is therefore likely to be more biologically meaningful than claims that an individual food, antioxidant or supplement can "boost fertility."
Diet may also matter on the male side of reproduction. Mediterranean-style and other generally healthy dietary patterns have been associated in observational studies with better sperm concentration, total sperm count, motility or overall semen quality.
However, semen parameters are surrogate markers rather than the ultimate reproductive outcome. A 2024 systematic scoping review in Human Reproduction Update found that only a small amount of high-quality intervention research exists on male preconception diet. For Mediterranean-diet adherence specifically, studies suggested associations with better semen parameters but did not provide evidence that the diet increases pregnancy or live-birth rates.
A Mediterranean-style diet is a reasonable preconception dietary pattern because it is nutrient-dense, consistent with general healthy-eating recommendations and has substantial evidence for cardiovascular and metabolic health. Those benefits are valuable regardless of whether the diet independently increases fertility.
What cannot currently be said is that adopting a Mediterranean diet will increase someone's fertility by a particular percentage, improve egg quality, cure PCOS or endometriosis, guarantee IVF success or overcome established causes of infertility.
Fertility remains strongly influenced by factors including age, ovarian reserve, ovulation, tubal function, uterine factors, endometriosis, sperm quality, genetics and underlying medical conditions. Diet may contribute to the biological environment in which reproduction occurs, but it is only one part of a much larger system.
Thyroid hormones influence reproduction at several levels, from the brain and pituitary to the ovary and endometrium. Both hypothyroidism and hyperthyroidism can alter menstrual patterns and ovulation, particularly when thyroid dysfunction is overt or severe. These effects are partly mediated through changes in prolactin, gonadotropin-releasing hormone (GnRH), sex hormone-binding globulin (SHBG), and ovarian steroid signalling.
The relationship is not purely indirect. Thyroid hormone receptors and thyroid-stimulating hormone (TSH) receptors have been identified within human ovarian tissue, including developing follicles, oocytes and granulosa cells. T3 and T4 have also been detected in the follicular fluid surrounding developing oocytes. Human granulosa cells contain the machinery needed to respond to and locally regulate thyroid hormone signalling, suggesting that the ovarian follicle itself is directly sensitive to thyroid status.
Thyroid signalling also appears to be involved in the uterus. TSH and thyroid hormone receptors are expressed in human endometrial tissue, with changes in receptor expression occurring across the menstrual cycle. Some receptor expression increases during the mid-luteal phase, around the time the endometrium becomes receptive to an implanting embryo. Experimental evidence also suggests that thyroid hormones interact with molecular pathways involved in decidualisation, trophoblast function and implantation.
This helps explain why significant thyroid dysfunction can interfere with fertility. In hypothyroidism, increased hypothalamic thyrotropin-releasing hormone (TRH) can stimulate prolactin secretion. Excess prolactin can suppress normal GnRH signalling, disrupting LH and FSH secretion and, in some women, interfering with follicular development and ovulation. Overt hypothyroidism has therefore been associated with irregular menstrual cycles, anovulation and reduced fertility, with reproductive abnormalities often improving once normal thyroid function is restored.
Subclinical hypothyroidism (SCH) means that TSH is above the appropriate reference range while free T4 remains normal. Importantly, a TSH above 2.5 mIU/L is no longer universally considered subclinical hypothyroidism in a non-pregnant woman trying to conceive.
The 2024 American Society for Reproductive Medicine (ASRM) guideline recommends using the laboratory- and age-specific TSH reference range for women who are not yet pregnant. When an appropriate reference range is unavailable, an upper limit of approximately 4.12 mIU/L can be used in iodine-sufficient populations. Pregnancy-specific reference ranges become relevant once pregnancy has occurred.
Using the traditional definition of an elevated TSH above the normal non-pregnant reference range with normal free T4, subclinical hypothyroidism is estimated to affect approximately 4–8% of reproductive-age women. This distinction matters because many older fertility studies classified women with TSH values between 2.5 and 4.0 mIU/L as having thyroid dysfunction, while more recent guidelines generally do not.
Current evidence does not support a sharp fertility threshold at a TSH of 2.5 mIU/L. The 2024 ASRM evidence review found insufficient evidence that subclinical hypothyroidism itself causes infertility and moderate evidence that TSH concentrations between 2.5 and 4.0 mIU/L are not associated with an increased risk of miscarriage.
The evidence becomes more concerning as thyroid dysfunction becomes more pronounced. Some observational and assisted-reproduction studies have reported poorer reproductive outcomes when TSH rises above approximately 4.0 mIU/L, but the literature is inconsistent and is complicated by differences in thyroid antibodies, infertility diagnoses, treatment protocols and the TSH thresholds used between studies.
Earlier studies suggested that treating relatively mild thyroid abnormalities with levothyroxine might improve pregnancy and live-birth rates. Larger randomized trials and more recent systematic reviews have substantially weakened that conclusion, particularly for women with mildly elevated TSH or thyroid autoimmunity who otherwise have normal thyroid hormone levels.
The larger TABLET trial produced a similar result. Researchers randomized 952 euthyroid women with thyroid peroxidase antibodies and a history of miscarriage or infertility to levothyroxine or placebo before conception. Live birth occurred in 37.4% of women receiving levothyroxine compared with 37.9% receiving placebo, with no significant reduction in pregnancy loss.
Thyroid autoimmunity adds another layer of complexity. Thyroid peroxidase antibodies (TPOAb) and thyroglobulin antibodies can be present even when TSH and thyroid hormone concentrations are normal. Observational studies have sometimes associated thyroid autoimmunity with miscarriage or subfertility, but it remains unclear whether the antibodies themselves contribute directly to reproductive failure or instead act as markers of broader autoimmune or thyroid dysfunction.
Importantly, randomized trials have not shown that routinely giving levothyroxine to euthyroid women simply because they have thyroid antibodies improves live-birth rates. Current guidelines therefore distinguish thyroid autoimmunity from true thyroid hormone deficiency rather than treating the two as equivalent conditions.
Assisted reproduction introduces another physiological twist. Ovarian stimulation causes very high estrogen concentrations, which increase hepatic production of thyroid-binding globulin. This can increase the body's requirement for thyroid hormone and may cause TSH to rise, particularly in women who already have hypothyroidism or thyroid autoimmunity.
For this reason, thyroid management during IVF can differ from routine preconception care. European and American guidelines also differ somewhat in how aggressively they recommend testing and treating mild thyroid abnormalities during assisted reproduction. More pronounced hypothyroidism, particularly TSH concentrations above the normal reference range or overt hypothyroidism with reduced free T4, remains much more clinically significant than a TSH of 2.5–4.0 mIU/L in an otherwise euthyroid woman.
Overall, thyroid health clearly matters for reproduction, but the relationship is more nuanced than the frequently repeated claim that “TSH must be below 2.5 to conceive.” Overt thyroid disease can disrupt the menstrual cycle, ovulation and pregnancy, while the fertility significance of mild or subclinical abnormalities is considerably less certain. Modern evidence increasingly supports treating clinically significant thyroid disease rather than treating an isolated borderline TSH value simply to improve fertility.
Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis, elevating cortisol levels that can suppress GnRH pulsatility and inhibit LH surges. Poor sleep quality disrupts circadian regulation of reproductive hormones, as melatonin — secreted at night — directly protects oocytes from oxidative damage and regulates LH release.
Since sperm production takes approximately 74 days, men should optimize their health for at least 3 months before attempting conception. This includes maintaining healthy testosterone levels, avoiding excessive heat exposure, and limiting alcohol consumption. Emerging evidence also highlights the importance of paternal diet and environmental toxin avoidance in determining sperm quality and offspring health.
For Women: Take 400–800 mcg folic acid daily (or 5 mg if at elevated neural tube defect risk), maintain BMI 18.5–24.9, track ovulation via LH testing and cervical mucus, ensure thyroid TSH is 1–2.5 mIU/L, limit caffeine to under 200 mg daily, optimize vitamin D (target serum 25(OH)D above 30 ng/mL), adopt Mediterranean-style diet, prioritize 7–9 hours of sleep nightly, minimize endocrine-disrupting chemicals (BPA, phthalates) in food packaging and personal care products.
For Men: Maintain healthy weight (BMI 18.5–24.9), limit alcohol to under 14 units/week, avoid smoking and recreational drugs including cannabis, manage stress, consider antioxidant supplements (vitamin C 1g, E 400 IU, selenium 100 mcg, CoQ10 200 mg daily), avoid excessive heat exposure to scrotal area (hot tubs, laptops on lap, tight underwear), minimize pesticide and heavy metal exposure, and consider sperm DNA fragmentation testing if over 40 or if prior miscarriages have occurred.
Endocrine-disrupting chemicals (EDCs) — including bisphenol A (BPA), phthalates, PFAS ("forever chemicals"), and organochlorine pesticides — mimic or block hormonal signals and accumulate in reproductive tissues. Exposure occurs primarily through food packaging, cookware, personal care products, and contaminated water.
Before a sperm can fertilize an egg, it must undergo capacitation — a series of biochemical changes triggered by the female reproductive tract environment. This process, taking approximately 5–7 hours, involves membrane cholesterol efflux, intracellular calcium influx, and activation of motility patterns that shift from progressive swimming to hyperactivated, whip-like motion needed to penetrate the zona pellucida.
Upon reaching the egg, the sperm binds to ZP3 glycoproteins on the zona pellucida, triggering the acrosome reaction — the release of hydrolytic enzymes from the sperm head that digest a path through the zona. Only sperm that have completed proper capacitation can undergo the acrosome reaction and achieve fertilization.
Fertilization involves multiple steps: sperm capacitation in the female reproductive tract, binding to the zona pellucida surrounding the egg, acrosome reaction allowing sperm penetration, and finally, fusion of sperm and egg membranes. This process triggers cortical granule release, preventing other sperm from entering — known as the zona reaction or "zona hardening." Within minutes of fertilization, the oocyte completes meiosis II, expelling the second polar body and restoring diploidy.
After fertilization, the embryo begins dividing while traveling down the fallopian tube. By day 3, it's an 8-cell embryo, and by days 5–6, it becomes a blastocyst ready for implantation. The journey from fallopian tube to uterus takes approximately 5–6 days. During this transit, the embryo undergoes embryonic genome activation (EGA) around the 4–8 cell stage — the pivotal moment when the embryo's own genome takes over control from maternally deposited factors.
Implantation occurs between days 6 and 10 post-fertilization, when the blastocyst must "hatch" from its zona pellucida, attach to the endometrial epithelium, and invade the underlying stroma to access maternal blood vessels. This process requires perfect synchrony between embryo development stage and endometrial receptivity — the "window of implantation" — which is open for just 24–48 hours in most women.
The first trimester is characterized by rapid hormonal changes, organ formation, and significant maternal adaptations. This period has the highest risk of miscarriage, with rates declining significantly after week 12. Remarkably, all major organ systems are established by the end of week 10 — a period of embryonic development that is exquisitely sensitive to nutritional deficiencies and environmental toxins.
Human chorionic gonadotropin (hCG) rises dramatically, doubling every 48–72 hours in early pregnancy. Peak levels occur around weeks 8–11, reaching 25,000–100,000 mIU/mL. Progesterone increases 10-fold, while estrogen levels rise 100-fold by the end of the first trimester. Relaxin begins rising from implantation, and thyroid-binding globulin increases, raising total thyroid hormone levels — necessitating thyroid medication dose adjustments in women with pre-existing hypothyroidism.
Affecting up to 80% of pregnant women, nausea and vomiting of pregnancy (NVP) is strongly correlated with hCG levels and peaks during weeks 8–10. Far from being merely a nuisance, NVP appears to serve a protective function — limiting maternal intake of potentially teratogenic foods and pathogens during the critical window of organogenesis.
The uterus grows from approximately 70g to 140g during the first trimester. Blood flow to the uterus increases by 10–15%, and the endometrium transforms into the decidua, providing nourishment for the developing embryo before placental function is fully established. The decidua is divided into three regions: decidua basalis (site of placental attachment), decidua capsularis (surrounding the embryo), and decidua parietalis (lining the remainder of the uterine cavity).
The placenta begins forming at implantation, with cytotrophoblast cells invading the endometrium and remodeling the spiral arteries by weeks 10–12. This remodeling — converting narrow, high-resistance vessels into wide, low-resistance conduits — is critical for adequate fetal blood supply throughout pregnancy. Failure of this process is the primary pathophysiological mechanism underlying preeclampsia and fetal growth restriction.
Maternal blood volume begins increasing by 6–8 weeks, ultimately expanding by 40–50% by term. Heart rate increases by 10–20 beats per minute, and cardiac output rises by 30–50% to meet the demands of pregnancy. Systemic vascular resistance drops by 20–30% in response to vasodilatory prostaglandins and nitric oxide, causing the relative hypotension and dizziness common in early pregnancy.
Approximately 10–15% of clinically recognized pregnancies end in miscarriage before 12 weeks, with chromosomal abnormalities accounting for 50–60% of losses. However, this figure represents only detected miscarriages — including biochemical pregnancies (positive hCG that does not progress), the total pregnancy loss rate before 20 weeks is estimated at 30–50%.
The second trimester is often called the "golden period" due to reduced nausea, increased energy, and the lowest risk of pregnancy complications. This is when many women feel their best during pregnancy. Fetal growth accelerates dramatically, with the fetus growing from about 9 cm (CRL) at 13 weeks to 35 cm at 27 weeks.
The placenta reaches full functionality, producing increasing amounts of progesterone and estrogen. By 20 weeks, the placenta produces more hormones than the ovaries ever did. Placental blood flow increases dramatically, reaching 500–700 mL/minute by the second trimester. The placenta also produces human placental lactogen (hPL), which induces insulin resistance to redirect glucose to the fetus — the physiological mechanism underlying gestational diabetes.
Gestational diabetes mellitus (GDM) affects 6–9% of pregnancies and is increasingly prevalent with rising maternal obesity rates. It typically develops between 24–28 weeks as placental hPL secretion peaks, inducing insulin resistance. Untreated GDM exposes the fetus to chronic hyperglycemia, causing macrosomia, neonatal hypoglycemia, and elevated lifetime risk of type 2 diabetes in the child.
The second trimester is the period of organ maturation and functional development. The fetal kidneys begin producing urine by 14 weeks, contributing to amniotic fluid. The fetal liver begins synthesizing clotting factors and erythropoietin. Fetal bone marrow takes over hematopoiesis from the liver by 20 weeks. The fetal brain undergoes massive neuronal proliferation and migration, establishing the six-layered cortex — a process exquisitely sensitive to maternal folate, iodine, and omega-3 status.
The mid-pregnancy anomaly scan at 18–22 weeks is the most comprehensive structural survey of the fetus. It evaluates over 20 anatomical structures including the heart (4-chamber view and outflow tracts), brain (ventricles, cerebellum, neural tube), spine, abdominal wall, kidneys, and limb lengths. Detection rates for major abnormalities range from 75–90% for cardiac defects to over 99% for anencephaly at specialist centers.
Breast size increases significantly due to ductal proliferation and alveolar development. Blood flow to breasts increases 3–4 fold, and Montgomery's glands become more prominent to prepare for breastfeeding. By 16 weeks, the breasts are producing colostrum — the protein-rich precursor to breast milk — under the influence of prolactin, though high progesterone levels prevent its secretion until after delivery.
Cervical length measurement by transvaginal ultrasound at 18–24 weeks has become a standard screening tool for preterm birth risk. A cervical length below 25 mm before 24 weeks is associated with a 6-fold increase in preterm birth risk before 35 weeks.
Most women feel fetal movement (quickening) between 16–20 weeks in first pregnancies and 14–18 weeks in subsequent pregnancies. Regular fetal movement patterns typically establish by 28 weeks and serve as important indicators of fetal well-being. The fetus sleeps in cycles of 20–40 minutes, and periods of reduced movement longer than 2 hours should prompt clinical evaluation.
The third trimester focuses on fetal growth, lung maturation, and maternal body preparation for labor and delivery. This period involves the most dramatic physical changes for the mother, with total weight gain of 10–12 kg by term distributed across the fetus (3.4 kg), placenta (0.7 kg), amniotic fluid (0.8 kg), uterus (0.9 kg), blood volume expansion (1.5 kg), and maternal fat stores (2.5–3.5 kg).
The uterus expands to accommodate the growing fetus, increasing from about 500g at 20 weeks to 1,100–1,200g at term. The fundal height (top of uterus) reaches the xiphoid process by 36 weeks, then may drop slightly as the baby engages in the pelvis (termed "lightening"). Braxton Hicks contractions — irregular, painless tightening of the myometrium — begin in the second trimester but become more frequent and noticeable in the third.
Surfactant production by type II pneumocytes is the critical rate-limiting step in fetal lung maturation. Adequate surfactant levels are required to reduce alveolar surface tension and prevent lung collapse with each breath. Surfactant production begins at 24 weeks but does not reach adequate levels until approximately 34–36 weeks, explaining why late preterm infants (34–36 weeks) still face significant respiratory morbidity.
The third trimester is a critical period for fetal brain development. Between 28 and 40 weeks, the brain triples in weight (from 100g to 400g), cerebral gyri and sulci form (gyrification), myelin deposition begins in sensory pathways, and synaptic connections multiply exponentially. This rapid development is highly dependent on adequate maternal nutrition, particularly DHA, choline, iron, and iodine.
The cervix undergoes significant changes in preparation for labor, becoming softer, shorter, and more anterior. Collagen fibers reorganize under the influence of prostaglandins and relaxin, and water content increases. The cervix may begin dilating weeks before active labor begins, especially in women who have given birth before. "Cervical ripening" prior to labor induction can be achieved with prostaglandin gels, Foley balloon catheters, or oral misoprostol.
Relaxin hormone causes ligament softening throughout the pelvis, allowing for increased pelvic mobility during delivery. The pubic symphysis may separate by 2–3 mm, and the sacroiliac joints become more mobile. Symphysis pubis dysfunction (SPD), affecting up to 25% of pregnant women, results from excessive relaxin-induced joint laxity and causes significant pelvic girdle pain.
The diaphragm is pushed upward by approximately 4 cm, reducing functional residual capacity by 20%. However, deeper breathing increases tidal volume by 30–40%, ensuring adequate oxygenation for both mother and baby despite the physical constraints. Progesterone directly stimulates the respiratory center in the medulla, causing relative hyperventilation and a mild compensated respiratory alkalosis (PaCO2 drops from 40 to approximately 30 mmHg) — which facilitates CO2 transfer from the fetus to the mother across the placenta.
Sleep architecture changes significantly in the third trimester, with REM sleep decreasing, nocturnal awakenings increasing due to fetal movement and urinary frequency, and restless legs syndrome (RLS) — linked to iron deficiency — affecting 15–25% of pregnant women. Poor sleep in late pregnancy is associated with longer labor duration and higher rates of cesarean delivery.
Group B Streptococcus colonizes the genital tract of approximately 20–30% of pregnant women and is the leading cause of neonatal sepsis and meningitis in the first week of life. Universal rectovaginal culture screening at 35–37 weeks, followed by intrapartum antibiotic prophylaxis for GBS-positive women, is standard practice in most developed countries.
Labor onset is driven by a complex, poorly understood cascade involving fetal cortisol, prostaglandins, oxytocin receptor upregulation, and progressive progesterone withdrawal. The fetus plays an active role in initiating labor — fetal lung maturation signals via surfactant proteins and cortisol communicate readiness to the maternal system.
Labor is divided into three stages. The first stage — from onset of regular contractions to full cervical dilation (10 cm) — has a latent phase (0–6 cm) lasting an average of 8–12 hours in first-time mothers and an active phase (6–10 cm) lasting approximately 1–2 hours. The second stage, from full dilation to delivery, lasts 20 minutes to 3 hours. The third stage — delivery of the placenta — typically occurs within 15–30 minutes of birth.
Oxytocin, produced by the hypothalamus and released from the posterior pituitary, drives uterine contractions during labor. Oxytocin receptor density in the myometrium increases 300-fold during late pregnancy. During labor, oxytocin creates a positive feedback loop — contractions stimulate more oxytocin release via the Ferguson reflex — causing contractions to become progressively stronger and more frequent. Synthetic oxytocin (Syntocinon/Pitocin) is used for both labor induction and augmentation.
Labor pain is transmitted via visceral afferent fibers during the first stage (T10–L1 dermatomes) and somatic fibers during the second stage (S2–S4). Epidural analgesia, the most effective pain relief method available, achieves its effect by depositing local anaesthetic and opioids into the epidural space, blocking pain transmission while preserving enough motor function for pushing.
After delivery, the uterus contracts rapidly — returning to near non-pregnant size (involution) within 6 weeks. Plasma estrogen and progesterone levels drop to near-zero within 24 hours of placental delivery, triggering milk "let-down" through removal of progesterone inhibition on prolactin. Colostrum transitions to mature milk between days 3–5 postpartum.
Understanding your reproductive anatomy and how it functions throughout conception, pregnancy, and birth empowers you to make informed decisions about your fertility journey. Each phase brings unique challenges and adaptations — from the microbiology of the endometrial cavity to the biomechanics of cervical ripening — but with proper preparation and care, your body is remarkably equipped for this incredible process.
The past decade has seen an explosion in reproductive science, from the discovery of the endometrial microbiome to real-time fetal brain imaging to the realization that paternal health matters as much as maternal health for offspring outcomes. Staying informed and working with healthcare providers who integrate this evidence into personalized care gives you the best possible foundation for a healthy pregnancy and birth.
Remember that every woman's experience is unique, and individual variations are normal. Your reproductive journey is a testament to the extraordinary capabilities of the human body — embrace the knowledge, trust the process, and celebrate each milestone along the way.
Comments